Focal White Matter Lesions Drive Grey Matter Inflammation and Synapse Loss

Why It Matters

Grey‑matter inflammation and synapse loss drive disability in multiple sclerosis and related disorders, so identifying white‑matter lesions as upstream triggers reshapes therapeutic focus toward supporting microglial‑mediated regeneration.

Key Takeaways

• Focal white‑matter lesions trigger transient grey‑matter microgliosis and synapse loss
• Neuronal activity drops ~60% after lesion, recovers with remyelination
• Microglial depletion or aging blocks myelin repair and prolongs inflammation
• Complement C1q marks synaptic pruning by activated microglia near lesions
• Successful regeneration requires coordinated grey‑white matter microglial response

Pulse Analysis

White‑matter lesions have long been viewed as passive markers of neurodegeneration, especially in multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Recent imaging and post‑mortem studies show a correlation between lesion burden and cognitive decline, yet the mechanistic link to grey‑matter pathology remained unclear. By targeting a well‑defined olivocerebellar circuit, the new research demonstrates that even a single focal demyelinating insult can initiate a cascade of upstream events, including microglial activation and synaptic pruning, challenging the traditional notion that grey‑matter damage occurs independently of white‑matter injury.

The experimental model revealed a striking 60 % reduction in inferior‑olive neuronal firing within a week of lesion induction, accompanied by a threefold rise in IBA1‑positive microglia and complement C1q deposition at excitatory synapses. Spatial transcriptomics identified early pro‑inflammatory and phagocytic gene signatures that later shifted toward neurotrophic profiles, indicating an adaptive microglial response that supports remyelination. When microglia were pharmacologically depleted or when aged animals were examined, the protective response failed, resulting in persistent inflammation, sustained synapse loss, and impaired myelin repair. These findings underscore microglia as pivotal mediators that translate white‑matter damage into functional neuronal deficits.

Clinically, the work suggests that therapeutic strategies aimed solely at protecting axons or suppressing peripheral inflammation may miss a critical upstream target. Enhancing the transient, reparative microglial phenotype—or preventing its age‑related decline—could accelerate remyelination and preserve synaptic integrity across a spectrum of neurodegenerative conditions. Future drug development may therefore benefit from combining myelin‑regenerative agents with modulators of complement signaling or microglial metabolism, offering a more holistic approach to halt disease progression.